The Glucagon Market is expanding as the prevalence of diabetes and severe hypoglycemia increases globally. Growing awareness of emergency hypoglycemia management, advancements in glucagon delivery systems, and the development of more convenient formulations are supporting market growth. Pharmaceutical companies are also investing in improved administration technologies to make glucagon easier to use during emergency situations.
According to the Market Research Future report updated September 10, 2026, the Glucagon Market was valued at USD 9.007 Billion in 2024 and is projected to grow from USD 9.612 Billion in 2025 to USD 18.42 Billion by 2035, registering a CAGR of 6.72% during 2025–2035. North America remains the largest market, while Asia-Pacific is identified as the fastest-growing region. Hypoglycemia represents the largest indication segment, while subcutaneous administration and injectable dosage forms remain important market categories.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/reports/glucagon-market-30032
Key players driving innovation and competitiveness in the Glucagon Market include:
Novo Nordisk
Sanofi
Eli Lilly and Company
Boehringer Ingelheim
Amgen
Pfizer
Bristol-Myers Squibb
Mylan
The increasing prevalence of diabetes is a major factor driving demand for glucagon products, particularly for emergency treatment of severe hypoglycemic episodes. Growing awareness among patients, caregivers, schools, workplaces, and healthcare professionals is also increasing the importance of readily accessible glucagon therapies.
The Glucagon Market can be segmented by indication, route of administration, glucagon origin, dosage form, and region. Indications include hypoglycemia, diabetic ketoacidosis, and other indications. Routes of administration include intravenous, subcutaneous, and intramuscular delivery, while glucagon origins include human, synthetic, and animal-derived products.
Injectable glucagon represents a major dosage-form category, while nasal spray is gaining attention because of its ease of administration. Advancements in pre-filled syringes, auto-injectors, nasal formulations, and other user-friendly delivery systems are creating opportunities for broader adoption.
Opportunities are emerging from increasing diabetes prevalence, improved emergency-care awareness, pediatric applications, innovative delivery systems, digital diabetes-management platforms, and expanding healthcare access in emerging markets. Partnerships between pharmaceutical companies, healthcare providers, and digital-health companies may further support market development.
Recent Developments and Market Trends:
The rising prevalence of diabetes is increasing demand for glucagon products used in the management of severe hypoglycemia.
Pharmaceutical companies are developing more convenient delivery systems, including pre-filled syringes, auto-injectors, and nasal formulations.
Digital health technologies are increasingly being incorporated into diabetes-management and patient-education programs.
Nasal glucagon is gaining attention because it can simplify emergency administration and reduce dependence on conventional injection-based delivery.
Healthcare providers and diabetes educators are increasing awareness about the importance of having glucagon available for emergency situations.
Research and development activities are focusing on improving glucagon formulations, safety, efficacy, and ease of use.
Asia-Pacific is creating additional opportunities as diabetes prevalence, healthcare expenditure, and awareness of hypoglycemia management increase.
Reasons to Buy the Report:
Understand the size and growth outlook of the Glucagon Market.
Analyze indication, administration route, glucagon origin, dosage form, and regional market opportunities.
Review leading pharmaceutical companies operating in the global glucagon industry.
Identify growth opportunities associated with innovative delivery systems and digital healthcare.
Assess the major trends influencing glucagon development and diabetes management through 2035.
Future Outlook:
The Glucagon Market is expected to expand as diabetes prevalence continues to increase and awareness of severe hypoglycemia management improves. The market is projected to reach USD 18.42 Billion by 2035 at a 6.72% CAGR, with advancements in drug delivery systems and increasing demand for convenient emergency treatments supporting market development.
North America is expected to maintain its position as a major market because of established healthcare infrastructure, strong pharmaceutical activity, and high awareness of diabetes management. Asia-Pacific is expected to experience significant growth as healthcare expenditure rises, diabetes prevalence increases, and access to diabetes-care products improves.
Through 2035, auto-injectors, nasal glucagon, pre-filled delivery systems, pediatric formulations, digital-health integration, and patient education are expected to influence the market. Continued pharmaceutical R&D and improvements in emergency glucagon accessibility will remain important factors shaping the industry’s development.
➤➤Explore Our Latest Related Reports:
